Brind.

Dr. Reddy’s Reports 17% Revenue Growth in India Amid North American Decline

1 report, 1 independent Updated Mon 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Dr. Reddy’s Laboratories reported consolidated revenue of ₹86.708 billion for the quarter ended September 30, which was up 7.4% from the previous quarter but down 1.5% year over year. Revenue in India rose 17% to ₹18.508 billion, attributed to new brands and price increases. However, revenue in North America fell 23% year over year to ₹24.89 billion due to lower lenalidomide sales.

From econotimes.com

Why it matters

Some supportBrind's analysis of the reports

The results show a significant regional divergence, with strong growth in India and emerging markets contrasting sharply with a substantial revenue decline in North America. The company also made a provision of ₹2.397 billion for inventory and related costs tied to semaglutide API.

From econotimes.com

Who's involved

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • North AmericaSpeculative

    North America might face continued revenue decline due to market weakness.

  • Torrent PharmaceuticalsSpeculative

    Torrent Pharmaceuticals could face cost pressure due to shared supply chain risks related to semaglutide API.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped